Search

Your search keyword '"Bengala C"' showing total 196 results

Search Constraints

Start Over You searched for: Author "Bengala C" Remove constraint Author: "Bengala C"
196 results on '"Bengala C"'

Search Results

3. C8 INSTITUTIONAL VALIDATION OF THE JOINT ANMCO AND AIOM TUSCANY CLINICAL CARDIO–ONCOLOGY PATHWAY FOR THE CARDIOLOGY MANAGEMENT OF CANCER OUTPATIENTS

5. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study

6. 216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)

11. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme

13. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

22. Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Final results of the phase III randomized MAIN-A trial

23. P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience

24. MA 11.11 Italian Nivolumab Expanded Access Program in Non-Squamous NSCLC Patients: Results in Never Smokers and EGFR Positive Patients

25. Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients

26. Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

32. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

33. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

34. Evaluation of thrombopoiesis kinetics by measurement of reticulated platelets and CD34(+) cell subsets in patients with solid tumors following high dose chemotherapy and autologous peripheral blood progenitor cell support

35. Rischio neoplastico post-trapianto

Catalog

Books, media, physical & digital resources